September 17th 2025
Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.
September 15th 2025
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
April 1st 2025The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.
Watch
ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award
March 15th 2025The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”
Read More
A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease
Read More
Cigarette smoking linked to reduced choroidal vascularity
March 4th 2025The negative effects of smoking on ocular tissues are well known and include age-related macular degeneration (AMD), diabetic retinopathy, cataracts, contact lens-related keratitis, Graves’ ophthalmopathy ischemic optic neuropathy, and glaucoma.
Read More
Envision Summit 2025: Deep learning models of neovascular AMD
February 24th 2025At the Envision Summit 2025 in San Juan, Puerto Rico, retina program chairs Geeta Lalwani, MD, and Majda Hadziahmetovic, MD, discussed Hadziahmetovic's presentation on deep learning models of neovascular AMD as well as their time at the conference.
Watch
Envision Summit 2025: Beyond the status quo in gene therapy
February 22nd 2025At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.
Watch